TG Therapeutics posted a sharp increase in revenue and net income in Q3 2025, driven by strong sales of BRIUMVI and a one-time tax benefit. Operating income more than doubled year-over-year as revenue expanded and costs rose at a slower pace.

TG Therapeutics saw substantial growth in Q2 2025, led by U.S. BRIUMVI sales totaling $138.8M, contributing to $141.1M in total revenue and $28.2M in net income.

TG Therapeutics delivered a profitable first quarter of 2025, achieving $120.9 million in revenue primarily from BRIUMVI sales and reporting a net income of $5.1 million. The company raised full-year revenue targets on the back of strong adoption and promising long-term data.

TG Therapeutics delivered a strong Q4 2024, with significant revenue growth fueled by the continued adoption of BRIUMVI. The company achieved profitability with a net income of $23.3 million, compared to a net loss in the prior year.

TG Therapeutics reported a successful third quarter in 2024, driven by strong U.S. BRIUMVI net revenue of $83.3 million. The company raised its full-year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million and continues to advance its clinical programs.

TG Therapeutics reported a strong second quarter in 2024, marked by exceeding expectations in U.S. BRIUMVI net revenue, leading to an increased full-year revenue guidance. The company also established a $250 million credit facility to manage debt and initiate a share repurchase program. R&D progress included the initiation of a phase 1 study for subcutaneous ublituximab and FDA IND clearance for azer-cel.

TG Therapeutics announced its Q1 2024 financial results, featuring $50.5 million in BRIUMVI U.S. net revenue, representing over 25% quarter-over-quarter growth. Total revenue reached $63.5 million, including a $12.5 million milestone payment. The company updated its full-year BRIUMVI U.S. net revenue guidance to $270 to $290 million.

TG Therapeutics announced its Q4 and full year 2023 financial results, highlighted by BRIUMVI U.S. net product revenue of $39.9 million for the quarter and $88.8 million for the year. The company's net loss for the quarter was $14.4 million, with a year-end cash position of $217.5 million.

TG Therapeutics reported a strong third quarter with total net revenue of $165.8 million, including $25.1 million in BRIUMVI net sales in the U.S. and $140.0 million from license revenue. The company's cash position is $229.2 million, which is expected to fund planned operations into cash flow positivity.

TG Therapeutics reported its Q2 2023 results, marking the first full quarter of BRIUMVI sales which reached $16 million. The company also announced an agreement with Neuraxpharm for ex-U.S. commercialization of BRIUMVI and secured a pro-forma cash balance of approximately $285 million.

TG Therapeutics reported its Q1 2023 financial results, marked by the commercial launch of BRIUMVI, which generated $7.8 million in net sales during its first partial quarter. The company's net loss was $39.2 million, and it holds cash, cash equivalents, and investment securities totaling $139.7 million.

TG Therapeutics reported product revenue of approximately zero for the fourth quarter of 2022. R&D expenses were $29.6 million, and SG&A expenses were $22.5 million. The net loss for the quarter was $53.0 million. Cash, cash equivalents and investment securities were $174.1 million as of December 31, 2022.

TG Therapeutics reported a net loss of $35.8 million for the third quarter ended September 30, 2022. The company focused on preparations for the potential launch of ublituximab for relapsing forms of multiple sclerosis (RMS).

TG Therapeutics reported its Q2 2022 financial results, showing a net loss of $40.5 million. The company's primary focus is on gaining FDA approval for ublituximab for RMS, with a PDUFA goal date of December 28, 2022. Cost-saving measures have been implemented, leading to a reduced cash burn.

TG Therapeutics reported product revenue of $2.3 million for the fourth quarter of 2021. The company's R&D expenses were $62.6 million and SG&A expenses were $32.4 million. Net loss for the quarter was $93.3 million. The company ended the year with over $350 million in cash, cash equivalents and investment securities.

TG Therapeutics reported its Q3 2021 financial results, highlighting the submission of a Biologics License Application (BLA) to the U.S. FDA for ublituximab to treat patients with relapsing forms of multiple sclerosis (RMS). The company generated $2.0 million in net product revenue from UKONIQ sales. The company's cash, cash equivalents and investment securities were $381.4 million as of September 30, 2021.

TG Therapeutics reported a net product revenue of $1.5 million from UKONIQ sales in Q2 2021. The company's R&D expenses increased due to licensing milestone fees, while SG&A expenses rose due to the launch of UKONIQ and preparations for potential launches of U2 and ublituximab. The net loss for the quarter was $78.5 million, and the company's cash, cash equivalents, and investment securities totaled $456.2 million as of June 30, 2021.

TG Therapeutics reported product revenue of $0.8 million for the first quarter of 2021, driven by the launch of UKONIQ. The company's R&D expenses increased to $63.1 million, and SG&A expenses rose to $26.8 million, reflecting commercial launch activities. Net loss for the quarter was $90.6 million. The company's cash, cash equivalents and investment securities were $523.8 million as of March 31, 2021.

TG Therapeutics reported a net loss of $88.2 million for the fourth quarter of 2020. The company's cash, cash equivalents, and investment securities totaled $605.4 million as of December 31, 2020, which is expected to fund operations into 2023.

TG Therapeutics announced positive results from the UNITY-CLL Phase 3 trial and the UNITY-NHL trial, supporting the NDA submission for umbralisib monotherapy. The company is preparing for a potential launch in relapsed/refractory MZL and FL, with PDUFA goal dates set in February 2021 and June 2021, respectively. The company's proforma cash position was approximately $325 million as of September 30, 2020.

TG Therapeutics announced positive progress in 2020, including the completion of the NDA rolling submission for umbralisib and positive topline data from the UNITY-CLL Phase 3 trial. With a strong cash balance, the company is positioned to execute milestones and transition into a commercial organization.

TG Therapeutics reported a net loss of $51.1 million for the first quarter of 2020. The company highlighted positive topline results from the UNITY-CLL Phase 3 trial and the initiation of a rolling NDA submission for umbralisib in MZL and FL. They ended the quarter with $78.3 million in cash, cash equivalents and investment securities, and pro forma cash of $154.3 million.

TG Therapeutics reported a net loss of $39.6 million for the fourth quarter of 2019. The company's cash, cash equivalents, and investment securities totaled $140.4 million as of December 31, 2019, expected to fund operations well into 2021. Key objectives for 2020 include reporting topline PFS results from the Phase 3 UNITY-CLL trial and completing the rolling NDA submission for umbralisib in patients with previously treated MZL and FL.